Search

Your search keyword '"Pau A"' showing total 1,369 results
Start Over Author "Pau A" Journal blood
1,369 results on '"Pau A"'

1. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

2. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

Author

Wang, Eunice S., Montesinos, Pau, Minden, Mark D., Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K., Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E., Gill, Stanley C., Rich, Elizabeth Shima, and Tiu, Ramon V.

Published
2022
Full Text
View/download PDF

4. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

5. Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Author

Espinoza, Marcela, primary, Romero, Monica Alejandra, additional, Jerez, Joaquín, additional, Bass, Francisca, additional, Lizama, Veronica, additional, Benavente, Rafael, additional, Sanchez, Matias Eugenio, additional, Aranguiz, Natalia, additional, Lopez, Miguel Nicolas, additional, Guerra, Maria Carolina, additional, Hidalgo, Sebastián, additional, Pérez, Verónica, additional, Linares, Belkys Mercedes, additional, Holloway Melo, Robert, additional, Carcamo, Lucas, additional, Rojas, Christine, additional, López-Vidal, Hernán, additional, Sanchez, Juan Manuel, additional, Samaniego, Francisco, additional, Montesinos, Pau, additional, and Martinez-Cuadron, David, additional

Published
2023
Full Text
View/download PDF

6. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Author

Crochet, Gilles, Iacoboni, Gloria, Couturier, Audrey, Bachy, Emmanuel, Iraola-Truchuelo, Josu, Gastinne, Thomas, Cartron, Guillaume, Fradon, Tom, Lesne, Bastien, Kwon, Mi, Gounot, Romain, Martínez-Cibrian, Nuria, Castilla-Llorente, Cristina, Abrisqueta, Pau, Guerreiro, Manuel, Sarkozy, Clémentine, Aspa-Cilleruelo, Jose María, Camus, Vincent, Guidez, Stéphanie, Chauchet, Adrien, Deconinck, Eric, Bouabdallah, Krimo, Bosch, Francesc, Barba, Pere, Morschhauser, Franck, and Houot, Roch

Published
2024
Full Text
View/download PDF

7. Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Author

Jorge E. Cortes, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Julie Brevard, Emma Barrett, and Stephane De Botton

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

8. Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Author

Jake Shortt, Pau Montesinos, Shuh Ying Tan, Teng Fong Ng, Chun Yew Fong, Paul Cannell, Rajeev Rajagopal, Sophia Leitch, Peter T. Tan, Sundra Ramanathan, Robin Gasiorowski, Douglas Stuart Lenton, Tse-Chieh Teh, José Antonio Pérez-Simón, Carolyn Grove, Xiaojun Huang, Courtney D. DiNardo, Katherine Naidu, Joseph Pariseau, Si Cheng, Yu Liu, Melannie Co, Wai Y. Chan, Haiyi Guo, and Andrew H. Wei

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

9. Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study

Author

Hartmut Döhner, Dylan M. Marchione, Sung Choe, Pau Montesinos, Christian Recher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Claudio Cerchione, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Adolfo De La Fuente, Jianan Hui, Prapti Patel, Diego A. Gianolio, Scott R. Daigle, Courtney D. DiNardo, and Stephane De Botton

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

10. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Author

Naval Daver, Pau Montesinos, Ahmed Aribi, Giovanni Marconi, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, Patrick W. Burke, Gianluca Gaidano, Roland B. Walter, Xavier Thomas, Deepa Jeyakumar, Daniel J. DeAngelo, Harry P. Erba, Elisabetta Todisco, Kebede H. Begna, Anjali Advani, Lauris Gastaud, Adolfo De La Fuente, Antonio Curti, Lourdes M. Mendez, Paresh Vyas, Nicolas Boissel, Norbert Vey, Christian Recher, Thomas Longval, Uwe Platzbecker, Silke Kapp-Schwoerer, Christoph Schliemann, Marina Konopleva, Laura Torres, David A. Sallman, Guido Marcucci, Naveen Pemmaraju, Giovanni Martinelli, Hagop Kantarjian, Callum M Sloss, Kara E Malcolm, Patrick A Zweidler-McKay, and Kendra Sweet

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

11. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Author

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, and Daniel Lopes de Menezes

Subjects
Neoplasm, Residual, Remission Induction, Immunology, Nuclear Proteins, Cell Biology, Hematology, Protein-Tyrosine Kinases, Prognosis, Biochemistry, Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Recurrence, Mutation, Azacitidine, Humans, Nucleophosmin
Abstract

The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell transplantation. Eligible patients were randomized 1:1 to Oral-AZA 300 mg or placebo for 14 days per 28-day cycle. We evaluated relapse-free survival (RFS) and overall survival (OS) in patient subgroups defined by NPM1 and FLT3 mutational status at AML diagnosis and whether survival outcomes in these subgroups were influenced by presence of post-IC measurable residual disease (MRD). Gene mutations at diagnosis were collected from patient case report forms; MRD was determined centrally by multiparameter flow cytometry. Overall, 469 of 472 randomized patients (99.4%) had available mutational data; 137 patients (29.2%) had NPM1 mutations (NPM1mut), 66 patients (14.1%) had FLT3 mutations (FLT3mut; with internal tandem duplications [ITD], tyrosine kinase domain mutations [TKDmut], or both), and 30 patients (6.4%) had NPM1mut and FLT3-ITD at diagnosis. Among patients with NPM1mut, OS and RFS were improved with Oral-AZA by 37% (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.98) and 45% (HR, 0.55; 95% CI, 0.35-0.84), respectively, vs placebo. Median OS was improved numerically with Oral-AZA among patients with NPM1mut whether without MRD (48.6 months vs 31.4 months with placebo) or with MRD (46.1 months vs 10.0 months with placebo) post-IC. Among patients with FLT3mut, Oral-AZA improved OS and RFS by 37% (HR, 0.63; 95% CI, 0.35-1.12) and 49% (HR, 0.51; 95% CI, 0.27-0.95), respectively, vs placebo. Median OS with Oral-AZA vs placebo was 28.2 months vs 16.2 months, respectively, for patients with FLT3mut and without MRD and 24.0 months vs 8.0 months for patients with FLT3mut and MRD. In multivariate analyses, Oral-AZA significantly improved survival independent of NPM1 or FLT3 mutational status, cytogenetic risk, or post-IC MRD status.

Published
2022

12. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification

Author

Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Récher, Raphaël Itzykson, Zdeněk Ráčil, Andrew H. Wei, and Christoph Schliemann

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

Mutations in the nucleophosmin 1 gene (NPM1) occur frequently in acute myeloid leukemia (AML) and are associated with a favorable prognosis. Applying the new 2022 European LeukemiaNet (ELN) classifier, Angenendt et al tested the prognostic significance of the copresence of NPM1 mutations and adverse-risk cytogenetics among 2426 patients. The authors demonstrate that outcomes for cytogenetic adverse-risk AML are not modulated by the presence or absence of NPM1 mutations, thereby clarifying management for patients.

Published
2023

14. The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells

Author

Dorsam, S T, Ferrell, C M, Dorsam, G P, Derynck, M K, Vijapurkar, U, Khodabakhsh, D, Pau, B, Bernstein, H, Haqq, C M, Largman, C, and Lawrence, H J

Abstract

Hematopoietic defects in HOXA9(-/-) mice demonstrate a key role for this homeoprotein in blood cell development. Conversely, enforced HOXA9 expression is leukemogenic in mice, and HOXA9 is frequently activated in human acute myeloid leukemia (AML). Although HOXA9 is thought to function as a transcription factor, few downstream targets have been identified. We searched for early HOXA9 target genes by using a transient overexpression strategy in 3 hematopoietic cell lines (2 myeloid, 1 lymphoid). cDNA microarray analyses identified 220 genes whose expression was modulated at least 2-fold. Expression signatures in myeloid and lymphoid cells demonstrated that HOXA9 functions as both an activator and repressor of a variety of genes in cell-specific patterns suggesting that the transcriptional effects of HOXA9 are largely dependent on the cell context. Transient transcription assays and target gene expression patterns in HOXA9(-/-) marrow cells imply that we have identified direct physiologic targets. Many tar-get genes are expressed in CD34(+) stem cells or are members of gene families involved in proliferation or myeloid differentiation. Expression of 14 HOXA9 target genes correlated with high-level HOXA9 expression in primary AML. These data suggest that many genes identified in this survey may mediate the biologic effects of HOXA9 in normal and leukemic hematopoiesis. (C) 2004 by The American Society of Hematology.

Published
2004

15. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Author

Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen B. Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Qi Jiang, Yan Sun, Brenda Chyla, Wellington Mendes, and Courtney D. DiNardo

Subjects
Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Immunology, Cytarabine, Humans, Cell Biology, Hematology, Biochemistry, Follow-Up Studies
Published
2022

16. Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Author

Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, and Harry P. Erba

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

17. Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Author

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, and Pau Montesinos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

18. Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Author

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner, Joshua Brody, Miguel Canales, Alejandro Martín García-Sancho, Marcel Nijland, P-O Andersson, Farrukh T. Awan, Jacob Haaber Christensen, Kristina Drott, Mats Hellström, Catharina Lewerin, Mayur Narkhede, Sylvia Snauwaert, Björn E Wahlin, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, Joost S.P. Vermaat, and Pau Abrisqueta

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

19. Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Author

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, and Mariana Bastos-Oreiro

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

21. Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Author

Claudia Sargas, Rosa Ayala, Maria Jose Larrayoz, Carmen Chillon, Estrella Carrillo, Cristina Bilbao, Esther Prados de La Torre, David Martinez-Cuadron, Rebeca Rodríguez-Veiga, Cristina Gil, Teresa Bernal, Juan Miguel Bergua Burgués, Lorenzo Algarra, Mar Tormo, Pilar Martínez Sánchez, Elena Soria, Josefina Serrano, Juan Manuel Alonso Dominguez, Raimundo García-Boyero, Maria Luz Amigo, Pilar Herrera, María J. Sayas, Esperanza Lavilla, Joaquín Martínez-López, María José Calasanz, Ramón García-Sanz, Jose A. Perez-Simon, María Teresa Gómez-Casares, Joaquín Sánchez-Garcia, Eva Barragán, and Pau Montesinos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

22. Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

Author

Moraima Jiménez, Sandra Novoa Jáuregui, Candela Fernández-Naval, Marc Bosch Schips, Sofía Muzio, Víctor Navarro Garcés, Cristina Andrés, Mónica Martínez-Gallo, Andrés Antón, Alba Cabirta, Angel Serna, Daniel Medina, Soraya Peralta, Gemma Pujadas, Cristina Hernandez, Carlota Pagès, Tomás Pumarola, Mercedes Valentín, David Valcárcel, Manuel Hernández, Isabel Ruiz-Camps, Marta Crespo, Juliana Esperalba, Pau Abrisqueta, and Francesc Bosch

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

23. Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Author

Catia Patricia Simoes, Sara Villar, Beñat Ariceta, Juan-José Garcés, Leire Burgos, Diego Alignani, Sarvide Sarai, David Martinez-Cuadron, Juan Miguel Bergua Burgués, Susana Vives, Lorenzo Algarra, Mar Tormo, Pilar Martinez Sanchez, Josefina Serrano, Pilar Herrera, Fernando Ramos, Olga Salamero, Esperanza Lavilla, Cristina Gil, Jose Luiz Lopez Lorenzo, María Belén Vidriales, María Carmen Chillón Santos, Jorge Labrador, José F. Falantes, Maria Jose Sayas, Rosa Ayala, Joaquín Martínez-López, Ana Alfonso-Pierola, María José Calasanz, Felipe Prosper, Jesús San-Miguel, Miguel A. Sanz, Pau Montesinos, and Bruno Paiva

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

25. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Author

Blanca Boluda, Claudia Sargas, Rosa Ayala, Maria Jose Larrayoz, María Carmen Chillón Santos, Estrella Carrillo-Cruz, Cristina Bilbao, Esther Prados de La Torre, Irene Navarro-Vicente, David Martinez-Cuadron, Rebeca Rodríguez-Veiga, Cristina Gil, Teresa Bernal del Castillo, Juan Miguel Bergua Burgués, Lorenzo Algarra, Mar Tormo, Pilar Martinez Sanchez, Elena Soria, Josefina Serrano, Juan Manuel Alonso Dominguez, Raimundo García-Boyero, Maria Luz Amigo, Pilar Herrera, Maria Jose Sayas, Esperanza Lavilla, Joaquín Martínez-López, María José Calasanz, Ramón García-Sanz, Jose A. Perez-Simon, María Teresa Gómez-Casares, Joaquín Sánchez-Garcia, Eva Barragán, and Pau Montesinos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

27. Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Author

Jorge Labrador, David Martinez-Cuadron, Blanca Boluda, Josefina Serrano, Cristina Gil, Jose A. Perez-Simon, Teresa Bernal del Castillo, Juan Miguel Bergua Burgués, Joaquín Martínez-López, Carlos Rodriguez, María Belén Vidriales, Raimundo García-Boyero, Jesús Lorenzo Algarra, Marta Polo, Maria Jose Sayas, Mar Tormo, Pilar Herrera, Esperanza Lavilla, Fernando Ramos, Maria Luz Amigo, Susana Vives, Joaquín Sánchez-Garcia, Cristina Bilbao, María Carmen Chillón Santos, Maria Jose Larrayoz, Rosa Ayala, Eva Barragán, Miguel A. Sanz, Pau Montesinos, and Juan Manuel Alonso-Dominguez

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

28. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Author

Lorenzo Falchi, Pau Abrisqueta, Marcel Nijland, Sirpa Leppä, Martin Hutchings, Harald Holte, Reid W Merryman, Pieternella Lugtenburg, Sven de Vos, Chan Y. Cheah, Jacob Haaber Christensen, Luca Arcaini, Kristina Drott, Mats Hellström, Lori A. Leslie, Umberto Vitolo, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, and David Belada

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

29. Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Author

Gloria Iacoboni, Josu Iraola-Truchuelo, Alberto Mussetti, Paula Fernández-Caldas, Víctor Navarro Garcés, ANA Africa Martin Lopez, Javier Delgado, Ariadna Pérez Martínez, Manuel Guerreiro, Ana Carolina Carolina Caballero Gonzalez, Nuria Martínez-Cibrián, Hugo Daniel Luzardo Henriquez, Jose M. Sanchez, Juan-Manuel Sancho, Pere Barba, Mi Kwon, Lucía López Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro, and Pau Abrisqueta

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

30. Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Author

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, and Vinod A. Pullarkat

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

31. Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Author

Edwin Uriel Suárez, Juan Manuel Alonso, Blanca Boluda, Esperanza Lavilla, Mar Tormo, Carmen Botella, Susana Vives, Carlos Rodriguez, Josefina Serrano, María José Sayas, Pilar Martínez Sánchez, Fernando Ramos, Teresa Bernal del Castillo, Lorenzo Algarra, Juan Miguel Bergua Burgués, José Pérez-Simón, Pilar Herrera, Manuel Barrios-García, Víctor Noriega-Concepción, Jóse Ángel Raposo-Puglia, Rosa Ayala, Eva Barragán, David Martinez-Cuadron, and Pau Montesinos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

32. Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Author

Jose Tomas Navarro, Carolina Celades, Andrea Usas, Olga García, Eva Gonzalez Barca, Fina Climent, Andrea Feu, Ana Isabel Jiminez Ubieto, Alba Gutiérrez de la Peña, Mariana Bastos-Oreiro, Teresa Aldamiz-Echevarría, Antonio Gutierrez, Leyre Bento De Miguel, Pau Abrisqueta Costa, Carmen Alonso Prieto, Christian David Tejada Chaves, Enrique M. Ocio, Noemi Fernandez-Escalada, Belén Navarro, José Miguel Mateos Pérez, Andrea Rivero, Carlos Fernández De Larrea, Alberto Lopez-Garcia, Paola Sandra Villafuerte Gutierrez, Sergio Felipe Pinzón, Elena Pérez Ceballos, Andrés González, José Ángel Hernández-Rivas, Raquel Del Campo, Emilia Pardal, Ramón García-Sanz, Jordina Rovira Sole, Juan-Manuel Sancho, and Gustavo Tapia

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

33. Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Author

Mark J. Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken CN Chang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, and Alexander Perl

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

34. Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Author

Alba Cabirta, Pau Abrisqueta, Víctor Navarro Garcés, Marta Canelo-Vilaseca, Marina Gomez-Rosa, Alberto Lopez García, Tomas García, Fatima De la Cruz, Juan-Manuel Sancho, Eduardo Rios Herranz, Raul Cordoba, Angel Serna, Moraima Jiménez, Sabela Bobillo, Marta Julia, Cecilia Carpio, Gloria Iacoboni, Laura Gallur, Josep Castellvi, Francesc Bosch, and Ana Marin-Niebla

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

36. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Author

Teresa Villalobos, Ana Muntañola Prat, Sonia González de Villambrosia, Maria J. Rodriguez-Salazar, Ana Isabel Jiminez Ubieto, Gabriela Bastidas-Mora, Raul Cordoba, Maria Stefania Infante, Maria Jesus Vidal, Francisco Javier Diaz-Galvez, Monica Baile, Mariana Bastos-Oreiro, Carlos Panizo, Juan-Manuel Sancho, Belen Navarro Matilla, Tomas García, Lourdes Escoda, Pau Abrisqueta, María José Terol, Raquel Del Campo, Armando López-Guillermo, Antonio Salar, and Carlos Montalban

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

38. Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Author

Alejandra Romero, Francisca Bass, Veronica Lizama, Christine Rojas, Javier Diaz, Marisa Capurro, Yaima Gutierrez, Matias Sanchez, Natalia Aránguiz, Marcela Espinoza, Maria Carolina Guerra, Sebastian Hidalgo, Joaquín Jerez, Pilar León, Bernardita Rojas, Ernesto Castaño, Denis Suarez Munoz, Vivianne Torres, Monica Paulina Fuentes, Miguel Lopez, Rocío Osorio, Belkys Mercedes Linares, Robert Holloway Melo, Paola Aravena, Patricia Fardella, Felipe Ramirez, Constanza Flores, Maria Soledad Urquieta, David Martinez-Cuadron, and Pau Montesinos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

40. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia

Author

Sheikh, Virginia, Porter, Brian O., DerSimonian, Rebecca, Kovacs, Stephen B., Thompson, William L., Perez-Diez, Ainhoa, Freeman, Alexandra F., Roby, Gregg, Mican, JoAnn, Pau, Alice, Rupert, Adam, Adelsberger, Joseph, Higgins, Jeanette, Bourgeois, Jeffrey S., Jr, Jensen, Stig M.R., Morcock, David R., Burbelo, Peter D., Osnos, Leah, Maric, Irina, Natarajan, Ven, Croughs, Therese, Yao, Michael D., Estes, Jacob D., and Sereti, Irini

Published
2016
Full Text
View/download PDF

41. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Author

Wei, Andrew H., primary, Panayiotidis, Panayiotis, additional, Montesinos, Pau, additional, Laribi, Kamel, additional, Ivanov, Vladimir, additional, Kim, Inho, additional, Novak, Jan, additional, Champion, Rebecca, additional, Fiedler, Walter, additional, Pagoni, Maria, additional, Bergeron, Julie, additional, Ting, Stephen B., additional, Hou, Jing-Zhou, additional, Anagnostopoulos, Achilles, additional, McDonald, Andrew, additional, Murthy, Vidhya, additional, Yamauchi, Takahiro, additional, Wang, Jianxiang, additional, Jiang, Qi, additional, Sun, Yan, additional, Chyla, Brenda, additional, Mendes, Wellington, additional, and DiNardo, Courtney D., additional

Published
2022
Full Text
View/download PDF

42. Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Author

Venditti, Adriano, primary, Hou, Jing-Zhou, additional, Fenaux, Pierre, additional, Jonas, Brian A., additional, Vrhovac, Radovan, additional, Montesinos, Pau, additional, Garcia, Jacqueline S., additional, Rizzieri, David, additional, Thirman, Michael J., additional, Montez, Melissa, additional, Liu, Yingyi, additional, Katsetos, John, additional, Potluri, Jalaja, additional, Miller, Catherine, additional, and Pullarkat, Vinod A., additional

Published
2022
Full Text
View/download PDF

43. Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Author

Iacoboni, Gloria, primary, Iraola-Truchuelo, Josu, additional, Mussetti, Alberto, additional, Fernández-Caldas, Paula, additional, Navarro Garcés, Víctor, additional, Martin Lopez, ANA Africa, additional, Delgado, Javier, additional, Pérez Martínez, Ariadna, additional, Guerreiro, Manuel, additional, Caballero Gonzalez, Ana Carolina Carolina, additional, Martínez-Cibrián, Nuria, additional, Luzardo Henriquez, Hugo Daniel, additional, Sanchez, Jose M., additional, Sancho, Juan-Manuel, additional, Barba, Pere, additional, Kwon, Mi, additional, Corral, Lucía López, additional, Hernani, Rafael, additional, Reguera, Juan Luis, additional, Sureda, Anna, additional, Martín García-Sancho, Alejandro, additional, Bastos-Oreiro, Mariana, additional, and Abrisqueta, Pau, additional

Published
2022
Full Text
View/download PDF

44. Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Author

Salamero, Olga, primary, Somervaille, Tim C.P, additional, Molero, Antonieta, additional, Acuña-Cruz, Evelyn, additional, Perez-Simon, Jose A., additional, Coll, Rosa, additional, Arnan, Montserrat, additional, Merchan, Brayan, additional, Perez, Ana, additional, Cano, Isabel, additional, Rodríguez-Veiga, Rebeca, additional, Arevalo, Mabel, additional, Gutierrez, Sonia, additional, Buesa, Carlos, additional, Faller, Douglas V, additional, Bosch, Francesc, additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

45. Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Author

Simoes, Catia Patricia, primary, Villar, Sara, additional, Ariceta, Beñat, additional, Garcés, Juan-José, additional, Burgos, Leire, additional, Alignani, Diego, additional, Sarai, Sarvide, additional, Martinez-Cuadron, David, additional, Bergua Burgués, Juan Miguel, additional, Vives, Susana, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martinez Sanchez, Pilar, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Ramos, Fernando, additional, Salamero, Olga, additional, Lavilla, Esperanza, additional, Gil, Cristina, additional, Lopez Lorenzo, Jose Luiz, additional, Belén Vidriales, María, additional, Chillón Santos, María Carmen, additional, Labrador, Jorge, additional, Falantes, José F., additional, Sayas, Maria Jose, additional, Ayala, Rosa, additional, Martínez-López, Joaquín, additional, Alfonso-Pierola, Ana, additional, Calasanz, María José, additional, Prosper, Felipe, additional, San-Miguel, Jesús, additional, Sanz, Miguel A., additional, Montesinos, Pau, additional, and Paiva, Bruno, additional

Published
2022
Full Text
View/download PDF

46. Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Author

Martín Moro, Fernando, primary, Bento De Miguel, Leyre, additional, Marquet Palomanes, Juan, additional, Gutierrez, Antonio, additional, Diaz-Lopez, Antonio, additional, Sanchez, Jose M., additional, Garcia Vela, Jose Antonio, additional, Salar, Antonio, additional, Cordoba, Raul, additional, Novelli, Silvana, additional, Rodriguez-Salazar, Maria J., additional, González de Villambrosia, Sonia, additional, Del Campo, Raquel, additional, Luzardo Henriquez, Hugo Daniel, additional, Garcia, Daniel, additional, Sancho, Juan-Manuel, additional, Abrisqueta, Pau, additional, Martín García-Sancho, Alejandro, additional, and Bastos-Oreiro, Mariana, additional

Published
2022
Full Text
View/download PDF

47. Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Author

Platzbecker, Uwe, primary, Angelucci, Emanuele, additional, Montesinos, Pau, additional, Lemoli, Roberto Massimo, additional, Spyridonidis, Alexandros, additional, Mughal, Tariq I., additional, Paley, Carole, additional, Riggi, Marcello, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

48. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Author

Boluda, Blanca, primary, Sargas, Claudia, additional, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillón Santos, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Navarro-Vicente, Irene, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal del Castillo, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martinez Sanchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, Maria Jose, additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

49. Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Author

Abrisqueta, Pau, primary, Cordoba, Raul, additional, Falchi, Lorenzo, additional, de Vos, Sven, additional, Nijland, Marcel, additional, Offner, Fritz, additional, Wu, Jun, additional, Bykhovski, Irina, additional, Wang, Liwei, additional, Rana, Ali, additional, and Phillips, Tycel, additional

Published
2022
Full Text
View/download PDF

50. Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Author

Schlenk, Richard F., primary, Montesinos, Pau, additional, Romero-Aguilar, Antonio, additional, Vrhovac, Radovan, additional, Patkowska, Elżbieta, additional, Kim, Hee-Je, additional, Zak, Pavel, additional, Wang, Po-Nan, additional, Hanyok, James, additional, Liu, Li, additional, Kamel, Yasser Mostafa, additional, Benzohra, Aziz, additional, Lesegretain, Arnaud, additional, Cortes, Jorge E., additional, Sekeres, Mikkael A., additional, Dombret, Hervé, additional, Amadori, Sergio, additional, Wang, Jianxiang, additional, Perl, Alexander E., additional, Levis, Mark J., additional, and Erba, Harry P., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results